| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 08/17/2000 | WO2000047212A1 Quinazoline derivatives as angiogenesis inhibitors |
| 08/17/2000 | WO2000047207A1 LACTAM INHIBITORS OF FXa AND METHOD |
| 08/17/2000 | WO2000047202A1 Felbamate derived compounds |
| 08/17/2000 | WO2000047201A1 The pharmacological use of certain cystine derivatives |
| 08/17/2000 | WO2000047197A2 Alkylating agents for treatment of cellular proliferation |
| 08/17/2000 | WO2000047149A1 Gels formed by the interaction of poly(aldehyde) with various substances |
| 08/17/2000 | WO2000033837A3 Myt1 kinase inhibitors |
| 08/17/2000 | WO2000027819A3 Antrhranilic acid amides and the use thereof as medicaments |
| 08/17/2000 | WO2000018912A3 Atp binding cassette genes and proteins for diagnosis and treatment of lipid disorders and inflammatory diseases |
| 08/17/2000 | WO2000015784A3 Human and murine g-protein-coupled edg6 receptor (endothelial differentiation gene) and use of same |
| 08/17/2000 | WO2000015231A9 Adenosine a3 receptor modulators |
| 08/17/2000 | WO2000012076A9 Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| 08/17/2000 | WO2000009109A3 Pipecolic acid derivatives for vision and memory disorders |
| 08/17/2000 | DE19906310A1 Use of 3-(1-(2-aralkyl-2-carboxyethyl)-1-cyclopentanecarboxamido)-2,3,4,5-tetrahydro-2-oxo-1H-benz(b)azepine-1-acetic acid derivatives for treating hypertension |
| 08/17/2000 | DE19905961A1 Use of estrogens to treat cardiac insufficiency and left ventricular dysfunction following myocardial infarction |
| 08/17/2000 | CA2362883A1 Alkylating agents for treatment of cellular proliferation |
| 08/17/2000 | CA2362392A1 Heterocyclic derivatives as inhibitors of factor xa |
| 08/17/2000 | CA2362390A1 Heteroaryl amidines, methylamidines and guanidines as protease inhibitors |
| 08/17/2000 | CA2362375A1 Alkenyl and alkynyl compounds as inhibitors of factor xa |
| 08/17/2000 | CA2362372A1 Tyrosine alkoxyguanidines as integrin inhibitors |
| 08/17/2000 | CA2362272A1 Spirocyclic ketones and their use as tachykinin antagonists |
| 08/17/2000 | CA2362147A1 1,2-benzothiazepines for the treatment of hyperlipidemic diseases |
| 08/17/2000 | CA2361919A1 Lactam inhibitors of fxa and method |
| 08/17/2000 | CA2361428A1 Inhibitors of factor xa |
| 08/17/2000 | CA2361335A1 Inhibiting formation of atherosclerotic lesions |
| 08/17/2000 | CA2361293A1 33 human secreted proteins |
| 08/17/2000 | CA2360305A1 Lactam inhibitors of fxa and method |
| 08/17/2000 | CA2360258A1 Felbamate derived compounds |
| 08/17/2000 | CA2359660A1 16-hydroxyestratrienes as selective estrogens |
| 08/17/2000 | CA2359475A1 Method for purifying a red fruit extract containing anthocyanosides |
| 08/16/2000 | EP1028114A1 Novel guanidine derivatives as inhibitors of cell adhesion |
| 08/16/2000 | EP1028112A1 Phenylglycinolamides linked by a hetero-atom with antiatherosclerotic agents |
| 08/16/2000 | EP1027891A2 Neuropeptide y antagonists |
| 08/16/2000 | EP1027890A2 Homer a new target of treating psychiatric disorders |
| 08/16/2000 | EP1027887A2 Matrix controlled release device |
| 08/16/2000 | EP1027834A1 Food composition comprising L-arginine |
| 08/16/2000 | EP1027603A2 Pharmaceutical grade ginkgo biloba |
| 08/16/2000 | EP1027429A1 Jnk3 modulators and methods of use |
| 08/16/2000 | EP1027363A2 Adenosine a1-receptor agonists |
| 08/16/2000 | EP1027340A1 4, 5-diaryloxazole compounds |
| 08/16/2000 | EP1027338A2 New carboxylic acid derivatives, carrying amido side-chains; production and use as endothelin receptor antagonists |
| 08/16/2000 | EP1027337A1 Integrin receptor antagonists |
| 08/16/2000 | EP1027336A1 Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors |
| 08/16/2000 | EP1027335A1 Ortho-hydroxypyridinone derivatives as iron chelating and antioxidant agents |
| 08/16/2000 | EP1027333A1 Thrombin inhibitors |
| 08/16/2000 | EP1027332A1 Novel lactam metalloprotease inhibitors |
| 08/16/2000 | EP1027329A1 Dofetilide polymorphs |
| 08/16/2000 | EP1027325A2 Lipophilic diesters of chelating agents |
| 08/16/2000 | EP1027075A1 Gene therapy for stimulation of angiogenesis |
| 08/16/2000 | EP1027060A2 Use of macrolides for the treatment of cancer and macular degeneration |
| 08/16/2000 | EP1027057A1 Treatment of female sexual dysfunction |
| 08/16/2000 | EP1027047A1 Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation |
| 08/16/2000 | EP1027036A2 Taste masked formulations |
| 08/16/2000 | EP0923379A4 Intravenous magnesium gluconate for treatment of conditions caused by excessive oxidative stress due to free radical distribution |
| 08/16/2000 | EP0805802B1 Substituted phenyl compounds as endothelin antagonists |
| 08/16/2000 | CN1263534A A preparation derived from shark cartilage for treatment of diseases related to excessive PHF or excessive intracellular calcium |
| 08/16/2000 | CN1263533A New formulation |
| 08/16/2000 | CN1263522A Compounds and methods for inhibition of expression of VCAM-1 |
| 08/16/2000 | CN1263468A Polyallylamine polymers for treating hypercholesterolemia |
| 08/16/2000 | CN1263465A Treatment and prevention of cardiac disorders using selective 5-hydroxytryptamine re-uptake inhibitors |
| 08/16/2000 | CN1263462A Monoesters of probucol for treatment of cardiovascular and inflammatory disease |
| 08/16/2000 | CN1263093A Amlo dipine mesylate and its preparation and application |
| 08/16/2000 | CN1262942A Intravenous injection medicine for curing ischemic cerebrovascular disease and its preparing method |
| 08/16/2000 | CN1262934A Medicine for curing diseases of cardiovascular system and cerebrovascular sytsem |
| 08/16/2000 | CN1262931A Method for extracting marine active substance and its application |
| 08/16/2000 | CN1055479C Cardiovascular active polypeptide and its synthesis and medical use |
| 08/15/2000 | US6103936 Reacting aldehyde, sulfide, sulfone, or sulfoxide with formamide in presence of acid catalyst, and optionally a dehydrating agent |
| 08/15/2000 | US6103925 Muscle contraction inhibitors; modulator with selectivity for charybdotoxin-sensitive, calcium-dependent potassium channels |
| 08/15/2000 | US6103910 D-proline derivatives |
| 08/15/2000 | US6103902 Carbamoylation process |
| 08/15/2000 | US6103769 Intravascularly administering a therapeutically effective amount of an aqueous solution comprising nitrogen monoxide to a mammal with endothelial dysfunction |
| 08/15/2000 | US6103762 A biaromatic compounds in which the aromatic nuclei are connected by a propynylene or allenylene divalent radical, useful as human or veterinary medicine or used in cosmetics or keratinization disorders |
| 08/15/2000 | US6103760 Aminotetralin derivative for the therapy of cardiovascular diseases |
| 08/15/2000 | US6103738 Quinoline and quinazoline compounds useful in therapy |
| 08/15/2000 | US6103737 Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists |
| 08/15/2000 | US6103733 Prevention of atherosclerosis and coronary heart disease; selective induction of hepatic cylochrome p450iiia (cyp3a) activity triphenylmethyl imidazoles or ppyridine substituted by a chlorine or fluorine |
| 08/15/2000 | US6103732 Endothelin receptor inhibitors; hypotensive agents, cardiotonic agents; acute myocardial infarct, pulmonary hypertension, raynaud's syndrome, atherosclerosis; asthma; cardiovascular disorders |
| 08/15/2000 | US6103722 Ischemic preconditioning |
| 08/15/2000 | US6103721 Heteroaryl-substituted pyridazino quinoline compounds |
| 08/15/2000 | US6103720 Ketobenzamides as calpain inhibitors |
| 08/15/2000 | US6103705 Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound |
| 08/15/2000 | US6103690 Prevention or inhibition of pathogenic syndromes caused by nitric oxide overproduction using iron-containing hemoprotein |
| 08/15/2000 | US6103527 Nucleotide sequence from gene expressed in proliferating endothelial cells; for controlled gene expression especially for transgenic tissues and gene therapy |
| 08/15/2000 | US6103513 Novel proteolytic enzyme; for the treatment of immune, proliferative and degratory defects |
| 08/15/2000 | US6103507 Protein used to raise an immunological response against a bacteria; bactericides |
| 08/15/2000 | US6103491 Methods and compositions for identifying morphogen analogs |
| 08/15/2000 | US6102254 Pharmaceutical compositions in semisolid form and a device for administration thereof |
| 08/15/2000 | CA2136553C 7-(2-aminoethyl)-benzothiazolones |
| 08/15/2000 | CA2046883C Heterocyclic derivatives, method for preparing same, and their therapeutic applications |
| 08/10/2000 | WO2000046391A2 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof |
| 08/10/2000 | WO2000046248A1 Use of agonists or antagonists of mip-3a in therapy |
| 08/10/2000 | WO2000046221A1 Sulfamato hydroxamic acid metalloprotease inhibitor |
| 08/10/2000 | WO2000046219A1 Alpha-azacyclomethyl quinoline derivatives for treating urinary incontinence |
| 08/10/2000 | WO2000046215A1 Benzazepine derivatives as alpha-v integrin receptor antagonists |
| 08/10/2000 | WO2000046214A1 Substituted 4-amino-2-aryltetrahydroquinazolines, their preparation, their use and pharmaceutical compositions comprising them |
| 08/10/2000 | WO2000046198A1 Anti-inflammatory indole derivatives |
| 08/10/2000 | WO2000046197A1 Indole derivatives and their use as mcp-1 receptor antagonists |
| 08/10/2000 | WO2000046189A1 Sulfonamide derivatives having cyclic structures |
| 08/10/2000 | WO2000045836A1 Uses of thank, a tnf homologue that activates apoptosis |
| 08/10/2000 | WO2000045835A1 Vascular endothelial growth factor-2 |